Comparative Pharmacology
Head-to-head clinical analysis: ACETAZOLAMIDE versus AZOPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAZOLAMIDE versus AZOPT.
ACETAZOLAMIDE vs AZOPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
None Documented
None Documented
Clinical Note
moderateAcetazolamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Atorvastatin."
Clinical Note
moderateAcetazolamide + Diclofenamide
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Diclofenamide."
Clinical Note
moderateAcetazolamide + Fosphenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Fosphenytoin."
Clinical Note
moderateTerminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Acetazolamide + Phenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Phenytoin."